AVEO Oncology (AVEO) and NiKang Therapeutics said Wednesday they are working together to develop a potential treatment for advanced clear cell renal cell...
Aveo Pharmaceuticals (AVEO) said Tuesday it entered a clinical trial collaboration and supply agreement with Merck KgaA to evaluate ficlatuzumab in...
AVEO Pharmaceuticals (AVEO) said Wednesday it has appointed Jeb Ledell as chief operating officer. Ledell previously served as operations chief at...
...
| Address | 30 Winter Street Boston, Massachusetts 02108 |
| Phone | +1.617.400.0101 |
| Number of Employees | 17 |
| Recent SEC Filing | 12/03/2021 3 |
| President, Chief Executive Officer & Director | Michael P. Bailey |
| Chief Operating Officer | Jebediah Ledell |
| Chief Financial Officer | Erick J. Lucera |
| Vice President-Information Technology | Matthew Coulter |
| Price Open | $3.92 |
| Previous Close | $3.95 |
| 52 Week Range | $3.76 - 18.24 |
| Market Capitalization | $132.7 M |
| Shares Outstanding | 34.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/15/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.98 |
| Beta vs. S&P 500 | N/A |
| Revenue | $5.4 M |
| Net Profit Margin | -225.54% |
| Return on Equity | -105.10% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
